MagForce Nanotechnologies AG : Nanostart-holding MagForce AG Successfully Completes Capital Increase
02/29/2012| 06:45am US/Eastern
Nanostart (OTCQX: NASRY) -holding MagForce AG (Frankfurt, XETRA: MF6), a
leading medical technology company focusing on nanomedicine in oncology
has completed a share placement with institutional investors. All of the
825,408 newly issued shares were placed, with profit participation
rights dating from January 1, 2011, at a price of EUR 5.50 per share.
The gross proceeds from the capital increase, in the amount of EUR
4,539,744.00 will be used for further commercialization activities and
the clinical development of the NanoTherm® technology along with the
expansion of commercial and strategic partnerships.
This transaction increases the nominal share capital of the company,
from EUR 4.127.041, divided into 4,127,041 shares with an imputed
nominal value of EUR 1.00, to EUR 4,952,495.00.
To support the transaction, Nanostart AG as the major shareholder of the
company, signed a lock-up which indicates that Nanostart AG will sell no
shares of MagForce AG over the stock exchange within the next twelve
The capital increase and the meetings with the strategic investors were
managed by Silvia Quandt & Cie. AG as a tied agent as defined in § 2
paragraph 10 of the Banking Act (KWG) and called on account of biw Bank
for Investments & Securities Ltd.
Nanostart AG (OTCQX: NASRY) headquartered in the German financial
capital of Frankfurt, is a leading nanotechnology investment company,
with portfolio companies spanning the globe from Silicon Valley to
Singapore. The company provides venture capital financing for
nanotechnology companies in various growth phases with a focus on
innovation-driven industries of the future such as cleantech, life
sciences and IT/electronics. Through its subsidiary Nanostart Asia and
the venture capital fund in Singapore, Nanostart is proud to be the
investment partner of the Singaporean government.
MagForce AG (XETRA: MF6) is a leading medical technology company
focusing on nanomedicine in oncology. The company's proprietary
procedure, NanoTherm® therapy, enables the targeted treatment of solid
tumors through the intratumoral generation of heat via activation of
magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator? are
components of the therapy and have received EU-wide regulatory approval
as medical devices for the treatment of brain tumors. MagForce,
NanoTherm, NanoPlan and NanoActivator are trademarks of MagForce AG in
selected countries. For more information, please visit www.magforce.com.
This notice constitutes neither an offer to sell nor a solicitation of
offers to purchase or subscribe to securities. There will be no public
offering of securities of Nanostart AG in conjunction with the existing
listing of its shares in the "Entry Standard" segment of the regulated
unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This
notice does not constitute a securities prospectus. Neither this notice
nor the information contained within is intended for direct or indirect
distribution within Canada, Australia or Japan.
Dr. Hans Joachim Duerr
Head of Corporate
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21
93 96 150
© Business Wire 2012